International Archives of Allergy and Immunology

Original Paper

Studies on the Allergenicity of the Amino-Terminal Epitope (Bet v I 23–38) from Birch Pollen Allergen

Vik H.a · Steinvåg S.K.b · Elsayed S.a

Author affiliations

aAllergy Research Group, Institute of Clinical Biology, Division of Biochemistry, and bDepartment of Otolaryngology, Head and Neck Surgery, University Hospital, University of Bergen, Norway

Related Articles for ""

Int Arch Allergy Immunol 1993;101:89–94

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 03, 2009
Issue release date: 1993

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

An N-terminal peptide of the major allergen of birch (Bet v I 23-38) was selected for studying the activity of this segment on the basis of optimal hydrophilicity as it was tentatively suggested to be a surface exposed epitope. In addition two control peptides in the region 1–38 were similarly used for comparative assignment of the allergenicity. Peptide analoges from the amino acid terminal region, amino acid residues No. 23–38 of Bet v I, were synthesized by semiautomatic solid-phase peptide synthesis. In vitro and in vivo biological activity studies were performed on these analogous peptides. The IgE-binding capacity of the synthetic peptide 23–38 was examined using the following tests: specific IgE inhibition, skin prick test, nasal provocation and Prausnitz-Küstner inhibition. The results of these investigations suggested that the region 23–38 from the birch and hazel major allergen encompassed a single haptenic epitope.

© 1993 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 03, 2009
Issue release date: 1993

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP